Table 1.
The clinical information from PCa patients
| No. | Age, y | Gleason score | PSA before Doc, ng/mL | PSA after Doc, ng/mL | Metastasis before treatment | Metastasis after treatment | Docetaxel dose | Frequency |
|---|---|---|---|---|---|---|---|---|
| 1 | 64 | 5 + 4 | 0.33 | 5.62 | Bladder and seminal vesicle metastasis | Multiple metastases and bone pain | 120 mg | 6 |
| 2 | 82 | 5 + 4 | 140 | 170.4 | bone metastases | Multiple bone metastases and fracture | 100 mg | 5 |
| 3 | 56 | 5 + 4 | 25.99 | 51.94 | T4 metastases | Multiple bone metastases and spinal compression | 120 mg | 16 |
| 4 | 56 | 5 + 4 | 445 | 795.8 | Multiple bone metastases | Multiple metastases, paraplegia and death | 120 mg | 4 |
| 5 | 65 | 5 + 4 | 134.2 | 301.4 | Multiple bone metastases | Multiple metastases and spinal compression | 120 mg | 7 |
| 6 | 68 | 5 + 4 | 28.11 | 35.35 | Multiple bone metastases | Multiple metastases and spinal compression | 120 mg | 2 |
| 7 | 61 | 4 + 5 | 30.43 | 80.12 | T12 metastases | Multiple metastases and bone pain | 120 mg | 17 |
| 8 | 62 | 4 + 5 | 25 | 1393 | Right sciatic metastasis | Multiple metastases and pathological fracture | 140 mg | 11 |
| 9 | 62 | 4 + 5 | 32.65 | 371.9 | T8‐T10 metastases | Multiple metastases and bone pain | 140 mg | 6 |
| 10 | 63 | 5 + 4 | 126.56 | 523.7 | Multiple bone metastases | Multiple bone metastases and bone pain | 140 mg | 20 |
| 11 | 55 | 5 + 4 | 48.1 | 180.6 | None | Multiple bone metastases and bone pain | 120 mg | 10 |
| 12 | 63 | 4 + 5 | 28.11 | 16.25 | T12 and L2 metastasis | Multiple bone metastases and bone pain | 120 mg | 3 |
| 13 | 66 | 4 + 4 | 481.1 | 23.54 | Bone metastasis | Multiple bone metastases and bone pain | 140 mg | 16 |
| 14 | 71 | 5 + 5 | 504.9 | 25.43 | None | Multiple bone metastases and bone pain | 120 mg | 2 |
| 15 | 49 | 4 + 3 | 26.78 | 0.006 | L3 metastasis | Multiple bone metastases and fracture | 120 mg | 5 |
Abbreviations: Doc, Docetaxel; PCa, prostate cancer; PSA, prostate‐specific antigen.